Investors

Följ vår resa mot framtidens medicin.

På denna sida så finner ni finansiella rapporter, nyheter, och annan information om CELLINK. Prenumerera på vår sida för att ta del av de senaste uppdateringarna om CELLINK.

Ökad omsättning med
131
%
Nettoomsättning
105
 MSEK
Anställda
330
 +
Senaste pressreleasernaMer
September 18, 2020RegulatoryCELLINK publishes prospectus and new financial information due to admission to trading of shares of series B on Nasdaq Stockholm
September 11, 2020RegulatoryBulletin from the extraordinary general meeting in CELLINK AB (publ)
September 7, 2020CELLINK have been granted funding totalling €3,910,000 from the EU as a part of the Horizon 2020 program. CELLINK’s portion of the grant is €270,000
September 2, 2020CELLINK completes the acquisition of Scienion AG
August 31, 2020RegulatoryCELLINK announces an increase in number of shares and votes
August 28, 2020CELLINK welcomes new scientific advisor Professor Ido Amit from the Weizmann Institute of Science
August 27, 2020Cytena and AstraZeneca collaborate to develop plate based microbioreactors for cell line development workflows
August 20, 2020RegulatoryNotice of extraordinary general meeting of CELLINK AB (publ)
August 20, 2020Invitation to CELLINK's conference call on the acquisition of Scienion AG
August 19, 2020RegulatoryCELLINK has completed directed share issues of SEK 946 million to finance the acquisition of SCIENION AG and create further room for a continued M&A agenda
August 19, 2020RegulatoryCELLINK announces intention to carry out directed share issues of approximately 13.5% of the outstanding shares to finance the acquisition of SCIENION AG
August 19, 2020RegulatoryCELLINK has entered into an agreement to acquire precision dispensing company Scienion Ag
August 13, 2020CELLINK announces strategic partnership with Carcinotech to advance 3D-bioprinting technology for cancer research
July 16, 2020RegulatoryBulletin from the extraordinary general meeting in CELLINK AB (publ)
July 14, 2020CELLINK and Kugelmeiers Ltd. announce strategic partnership for 3D printing cell spheroids
July 9, 2020RegulatoryQ3 19/20: Continued growth and Main market listing during an ongoing pandemic
June 24, 2020RegulatoryNotice of extraordinary general meeting of CELLINK AB (publ)
June 23, 2020CELLINK CELLINK has been granted a patent for "3D bioprinter and a 3D bioprinter system" from The Swedish Patent and Registration Office
June 10, 2020CELLINK and Lonza Join Forces to Offer Complete 3D Cell Culture Workflows
June 9, 2020RegulatoryCELLINK has been granted a patent for "Cellulose Nanofibrillar Bioink for 3D Bioprinting for Cell Culturing, Tissue Engineering and Regenerative Medicine Applications" from USPTO
May 20, 2020Erik Gatenholm and CELLINK awarded the SVD Business Award 2020
May 14, 2020CELLINK announces collaboration with AstraZeneca to utilize CELLINKs’ 3D-bioprinting technology for liver organoid culture
April 20, 2020Trading in CELLINK’s shares commences today on Nasdaq Stockholm Main Market
April 18, 2020CELLINK's founders informs about executing a call option
April 15, 2020RegulatoryThe conditions for listing of CELLINK on Nasdaq Stockholm have been fulfilled
April 15, 2020RegulatoryCELLINK publishes prospectus in connection with its listing on Nasdaq Stockholm
April 9, 2020RegulatoryQ2 19/20: Continued growth and global expansion during an increasing global crisis
April 3, 2020RegulatoryCELLINK AB (publ) approved for listing on Nasdaq Stockholm
April 1, 2020CELLCYTE X wins prestigious Red Dot for outstanding design quality
March 31, 2020CELLINK AB (publ) receives an order of SEK 5,200,000 from the National Board of Health and Welfare in Sweden
March 25, 2020CELLINK launches a real-time qPCR instrument
March 22, 2020RegulatoryUpdate regarding COVID-19
March 4, 2020CELLINK has received a grant to develop a new organ-like in vitro model that can be used in drug development and testing for renal diseases.
February 20, 2020CELLINK joins Dassault Systèmes’ 3DEXPERIENCE Lab global accelerator program
February 3, 2020CELLINK announces extension of collaboration with AstraZeneca to use CELLINKs’ 3D-bioprinting and associated technology for drug discovery
January 29, 2020RegulatoryCELLINK has completed a directed share issue of SEK 377 million
January 29, 2020RegulatoryCELLINK announces intention to carry out a directed share issue of approximately 3,850,000 shares
January 20, 2020RegulatoryQ1 19/20: Strong sales growth and successful integration of acquisitions
January 9, 2020CELLINK is carrying out stock split (4:1)
December 23, 2019CELLINK signs agreement to expand its production area
December 19, 2019CELLINK’s BIO X wins The Chicago Athenaeum’s prestigious GOOD DESIGN Award
December 18, 2019RegulatoryBulletin from the Annual General Meeting in CELLINK AB (publ)
December 16, 2019CELLINK to partner with Made In Space to advance bioprinting technology in space
December 13, 2019RegulatoryCELLINK’s board has set financial targets for the company
November 21, 2019CELLINK launches new bioinks to further strengthen the company’s bioink portfolio
November 18, 2019RegulatoryNotice of annual general meeting of CELLINK AB (publ)
November 14, 2019Annual Report 2018/2019
November 4, 2019Bioprinting advanced skin architecture complete with blood vessels using CELLINK technology
October 25, 2019CELLINK opens office in Lyon, France to strengthen presence in Europe
October 24, 2019RegulatoryReport on Operations 2018-2019: Strategic acquisition and strong closing of the year
Finansiella rapporterMer
Årsredovisning 2018/2019
Årsredovisning 2017/2018
Årsredovisning 2016/2017
Årsredovisning 2016
Kalender Mer
October 22, 2020Delårsrapport juni – augusti 2020
February 25, 2021Bokslutskommuniké september - december(Q1-Q5) 2019/2020
March 17, 2021Årsredovisning 2019/2020